**6. References**


In the past 25 years, IAS has developed from an unproven theoretical framework to a promising therapeutic option for subgroups of prostate cancer patients equal to CAS in respect to overall survival. Many questions in regard to the most suitable patient population and the optimal application of IAS remain to be investigated. With the exception of the frequency of hot flashes the improvement of other side effects of androgen suppression by intermittent therapy needs further careful assessment. This can be supported by determination of laboratory parameters of bone matrix turnover, blood chemistry and lipid profiles and correlation with the clinical characteristics. Last but not least, the reduced costs

Abrahamsson, P.A. (2010) Potential Benefits of Intermittent Androgen Suppression Therapy

Akakura, K., Bruchovsky, N., Goldenberg, S.L., Rennie, P.S., Buckley, A.R. & Sullivan

Bales, G.T., Sinner, M.D., Kim, J.H. & Chodak, G.W. (1996) Impact of intermittent androgen

Bruchovsky, N., Rennie, P.S., Coldman, A.J., Goldenberg, S.L., To, M. & Lawson, D. (1990)

Bruchovsky, N., Rennie, P.S., Otal, N., Vanson, A., Giles, M. & Pontifex, H. (1985) Variability

Bruchovsky, N., Snoek, R., Rennie, P.S. Akakura, K., Goldenberg, L.S. & Gleaves, M. (1996) Control of tumor progression by maintenance of apoptosis. *Prostate* 6S, 13-21. Bruchovsky, N., Rennie, P.S., Van Doom, E. & Noble, R.L. (1978) Pathological growth of

Buchan, N. C. & Goldenberg, S.L. (2010) Intermittent androgen suppression for prostate

Bruchovsky, N., Goldenberg, S.L., Rennie, P.S. & Gleaves, M. (1995) Theoretical

Calais da Silva, F.E., Bono, A.V., Whelan, P., Brausi, M., Marques Queimadelos, A., Martin,

patients with advanced prostatic carcinoma. *Urologe-A* 34, 389-392.

L.D.(1993) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. *Cancer* 71(9), 2782-2790. Akakura, K., Bruchovsky, N., Rennie, P.S., Coldman, A.J., Goldenberg, S.L., Tenniswood, M.

& Fox, K. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. *J* 

Effects of androgen withdrawal on the stem cell composition of the Shionogi

of androgen-related phenotypes in the Shionogi mammary carcinoma during growth, involution, recurrence, and progression to hormonal independence. *Cancer* 

androgen-sensitive tissues resulting from the latent actions of steroid hormones. *J* 

considerations and initial clinical results of intermittent hormone treatment of

J.A., Kirkali, Z., Calais da Silva, F.M. & Robertson, C. (2009) Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a

of intermittent therapy are expected to promote a more general application.

in the Treatment of Prostate Cancer. *Eur Urol* 57(1), 49-59.

deprivation on quality of live (QOL). *J Urol* 155, 578A. Brawer, M.K. (2006) Hormonal therapy for prostate cancer. *Rev Urol* 8, S35-47.

*Steroid Biochem Mol Biol* 59(5-6), 501-511.

carcinoma. *Cancer Res* 50(8), 2275-2282.

*Toxicol Environ Health* 4, 391-408.

cancer. *Nature Rev Urol* 7, 552-560.

*Res* 45(2), 682-689.

**5. Conclusions** 

**6. References** 

randomised phase 3 study of the South European Uroncological Group. *Eur Urol* 55(6), 1269-1277.


Intermittent Androgen Suppression Therapy

*Bone Miner Metab* 22, 127-131.

*Opin Pharmacol* 5(6): 612–617.

breast cancer. *Anticancer Res* 27(4A), 1853-1862.

mammary carcinoma. *Cancer Res* 48(22), 6309-6312.

carcinoma*. J Steroid Biochem Mol Biol* 50(1-2), 31-40.

prostate cancer. *Cancer* 110(7), 1493-1500.

248-251.

genes. *J Steroid Biochem Mol Biol 37(6),* 843-847*.* 

for Prostate Cancer Patients: A Choice for Improved Quality of Life? 377

Okabe, R., Inaba, M., Nakatsuka, K., Miki, T., Naka, H., Moriguchi, A. & Nishizawa, Y.

Pollmann, D., Siepmann, S., Geppert, R., Wernecke, K.D., Possinger, K. & Lüftner, D. (2007)

Poole, K. & Reeve, J. (2005). Parathyroid hormone - a bone anabolic and catabolic agent. *Curr* 

Raghavan, D., Koczwara, B. & Javle, M. (1997) Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. *Eur J Cancer* 33, 566-574. Rennie, P.S., Bruchovsky, N., Buttyan, R., Benson, M. & Cheng, H. (1988) Gene expression

Rennie, P.S., Bruchovsky, N. & Coldman, A.J. (1990) Loss of androgen dependence is

Rennie, P.S, Bruchovsky, N., Akakura, K., Goldenberg, S.L., Otal, N., Akakura, S., Wong, P.

Rosenquist, C., Fledelius, C., Christgau, S., Pedersen, B.J., Bonde, M., Qvist, P. &

Saigal, C.S., Gore, J.L., Krupski, T.L, Hanley, J., Schonlau, M. & Litwin, M.S. (2007)

Sciarra, A., Cattarino, S., Gentilucci, A., Alfarone, A., Innocenzi, M., Gentile, V. & Salciccia, S.

cancer cases with biochemical progression after surgery. *Urol Oncol*, in press. Seruga, B. & Tannock, I.F. (2008) Intermittent androgen blockade should be regarded as

Shahinian, V.B., Kuo, Y.F., Freeman, J.L. & Goodwin, J.S. (2005) Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med* 352(2), 154-164. da Silva, F.C. (2011) Intermittent hormonal therapy for prostate cancer. *Curr Opin Urol* 21(3),

Snoek, R., Cheng, H., Margiotti, K., Wafa, L.A., Wong, C.A., Wong, E.C., Fazli, L., Nelson,

Spry, N.A., Galvão, D.A., Davies, R., La Bianca, S., Joseph, D., Davidson, A. & Prince, R.

C.C., Gleave, M.E. & Rennie, P.S. (2011) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-

Long-term effects of intermittent androgen suppression on testosterone recovery

C-terminal telopeptides of type I collagen. *Clin Chem* 44, 2281-2289.

standard therapy in prostate cancer. *Nat Clin Pract Oncol* 5, 574-576.

resistant prostate tumors. *Clin Cancer Res* 15(1), 39-47.

(2004) Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. *J* 

The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic

during the early phases of regression of the androgen-dependent Shionogi mouse

associated with an increase in tumorigenic stem cells and resistance to cell-death

& Tenniswood, M. (1994) Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi

Christiansen, C. (1998) SerumCrossLaps® ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from

Androgen deprivation therapy increases cardiovascular morbidity in men with

(2011) Predictors for response to intermittent androgen deprivation (IAD) in prostate


Jung, K., Miller, K., Wirth, M., Albrecht, M. & Lein, M. (2011) Bone turnover markers as

Kiratli, B.J., Srinivas, S., Perkash, I. & Terris, M.K. (2001) Progressive decrease in bone

Klotz, L.H., Herr, H.W., Morse, M.J. & Whitmore, W.F. (1986) Intermittent endocrine

Klotz, L., O'Callaghan, C.J., Ding, K., Dearnaley, D.P., Higano, C.S., Horwitz, E.M., Malone,

Kollmeier, M.A. & Zelefsky, M.J. (2008) What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer? *Nat Clin Pract Urol* 5, 584-585. Koopmans, N., de Jong, I.J., Breeuwsma, A.J. & E. van der Veer, E. (2007) Serum bone

patients with prostate cancer: a longitudinal approach. *J Urol* 178, 849-853. Lassi, K. & Dawson, N.A. (2009) Emerging therapies in castrate-resistant prostate cancer.

de Leval, J., Boca, P., Yousef, E., Nicolas, H., Jeukenne, M., Seidel, L., Bouffioux, C.,

Locke, J.A. & Bruchovsky, N. (2010) Prostate cancer: finasteride extends PSA doubling time

Madan, R.A., Pal, S.K., Sartor, O. & Dahut, W.L. (2011) Overcoming chemotherapy

Malone, S., Perry, G., Segal, R., Dahrouge, S. & Crook, J. (2005) Long-term side-effects of

Mearini, L., Zucchi, A., Costantini, E., Bini, V. & Porena, M. (2011) Intermittent androgen

Mellado, B., Codony, J., Ribal, M.J., Visa, L. & Gascon, P. (2009) Molecular biology of

Mottet, N., Prayer-Galetti, T., Hammerer, P., Kattan, M.W. & Tunn, U. (2006) Optimizing

Nguyen-Pamart, M., Caty, A., Feutrie, M.L., Fournier, E., Gosselin, P. & Mazeman, E. (1997)

intermittent androgen suppression therapy in prostate cancer: results of a phase II

suppression in prostate cancer: testosterone levels and its implication. *J Sex Med*

androgen-independent prostate cancer: the role of the androgen receptor pathway.

outcomes and quality of life in the hormonal treatment of prostate cancer. *BJU Int*

The diagnostic value of urinary CrossLaps and serum alkaline phosphatase in

during intermittent hormone therapy. *Can J Urol* 7(3), 5162-5169.

resistance in prostate cancer. *Clin Cancer Res* 17(12), 3892-3902.

following treatment with zoledronic acid. *Eur Urol* 59(4), 604-612.

therapy for advanced prostate cancer. *Cancer* 58, 2546-2550.

cancer. *Urology* 57, 127-132.

*Curr Opin Oncol* 21, 260-265.

study. *BJU Int* 96, 514-520.

*Clin Transl Oncol* 11, 5-10.

patients with prostate cancer. *BJU* 80, 452-455.

8(4), 1218-1227.

98, 20-27.

trial. *Clin Prostate Cancer* 1(3), 163-171.

Abstract # 3.

predictors of mortality risk in prostate cancer patients with bone metastases

density over 10 years of androgen deprivation therapy in patients with prostate

S., Goldenberg, S.L., Gospodarowicz, M.K. & Crook, J.M. (2011) A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. *J Clin Oncol* 29, S7;

turnover markers (PINP and ICTP) for the early detection of bone metastases in

Coppens, L., Bonnet, P., Andrianne, R. & Wlatregny, D. (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter


and bone mineral density: results of a 33-month observational study. *BJU Int* 104(6), 806-812.


Strum, S.B., Scholz, M.C. & McDermed, J.E. (2000) Intermittent androgen deprivation in

Taylor, L.G., Canfield, S.E. & Du, X.L. (2009) Review of major adverse effects of androgendeprivation therapy in men with prostate cancer. *Cancer* 115, 2388-2399. Theyer, G., Holub, S., Dürer, A., Andert, S., Haberl, I., Theyer, U. & Hamilton, G. (1997)

under intermittent androgen suppression therapy. *Br J Cancer* 75, 1515-1518. Theyer, G. & Hamilton G. (1998) Current status of intermittent androgen suppression in the

Theyer, G., Dürer, A., Theyer, U., Haberl, I., Ulsperger, E., Baumgartner, G. & Hamilton, G.

Theyer, G., Ulsperger, E., Baumgartner, G., Raderer, M. & Hamilton, G. (2000) Prolonged

Theyer, G., Holub, S., Olszewski, U. & Hamilton, G. (2010) Measurement of bone turnover in

Tzou, K., Tan, W.W. & Buskirk, S. (2011) Treatment of men with rising prostate-specific

Yu, E.Y., Gulati, R., Telesca, D., Jiang, P., Tam, S., Russell, K.J, Nelson, P.S., Etzioni, R.D. &

treatment of prostate cancer. *Urology* 53, 353-359.

suppression therapy. *Prostate* 41: 71-77.

cancer patients. *Ann Oncol* 11, 877-881.

806-812.

*Oncologist* 5, 45-52.

*Urology* 2, 155-159.

28(16), 2668-2673.

125-136.

and bone mineral density: results of a 33-month observational study. *BJU Int* 104(6),

prostate cancer patients: Factors predictive of prolonged time off therapy.

Measurements of tissue polypeptide-specific antigen in prostate cancer patients

(1999) Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen

response to a single androgen suppression phase in a subpopulation of prostate

prostate cancer patients receiving intermittent androgen suppression therapy. *OA J* 

antigen levels following radical prostatectomy. *Expert Rev Anticancer Ther* 11(1),

Higano, C.S. (2010) Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. *J Clin Oncol*
